Which has higher valuation and earnings, RAPP or PCVX?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is RAPP or PCVX more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -24.78% -23.44% Vaxcyte N/A -32.51% -29.51%

Does the media favor RAPP or PCVX?

In the previous week, Vaxcyte had 9 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Vaxcyte and 6 mentions for Rapport Therapeutics. Vaxcyte's average media sentiment score of 0.99 beat Rapport Therapeutics' score of 0.37 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RAPP or RYTM?

In the previous week, Rhythm Pharmaceuticals had 7 more articles in the media than Rapport Therapeutics. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 6 mentions for Rapport Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat Rapport Therapeutics' score of 0.37 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RAPP or IBRX?

In the previous week, ImmunityBio had 8 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for ImmunityBio and 6 mentions for Rapport Therapeutics. ImmunityBio's average media sentiment score of 0.57 beat Rapport Therapeutics' score of 0.37 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, COGT or RAPP?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is COGT or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Rapport Therapeutics N/A -24.78% -23.44%

Does the media favor COGT or RAPP?

In the previous week, Rapport Therapeutics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Rapport Therapeutics and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.52 beat Rapport Therapeutics' score of 0.37 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RAPP or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 6 mentions for Rapport Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Rapport Therapeutics' score of 0.37 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rapport Therapeutics (RAPP) Competitors

$41.39 +0.60 (+1.47%)

As of 11:42 AM Eastern

Compare

RAPP vs. PCVX, RYTM, IBRX, COGT, and MIRM

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), Cogent Biosciences (COGT), and Mirum Pharmaceuticals (MIRM).

How does Rapport Therapeutics compare to Vaxcyte?

Rapport Therapeutics (NASDAQ:RAPP) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Rapport Therapeutics currently has a consensus target price of $57.86, suggesting a potential upside of 39.79%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 57.75%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Vaxcyte had 9 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Vaxcyte and 6 mentions for Rapport Therapeutics. Vaxcyte's average media sentiment score of 0.99 beat Rapport Therapeutics' score of 0.37 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Vaxcyte	N/A	-32.51%	-29.51%

Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

96.8% of Vaxcyte shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rapport Therapeutics beats Vaxcyte on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Rapport Therapeutics (NASDAQ:RAPP) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Rhythm Pharmaceuticals had 7 more articles in the media than Rapport Therapeutics. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 6 mentions for Rapport Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat Rapport Therapeutics' score of 0.37 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Rapport Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Rhythm Pharmaceuticals	$189.76M	37.27	-$196.54M	-$3.13	N/A

Rapport Therapeutics presently has a consensus price target of $57.86, suggesting a potential upside of 39.79%. Rhythm Pharmaceuticals has a consensus price target of $138.73, suggesting a potential upside of 34.42%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rapport Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Rapport Therapeutics' return on equity of -24.78% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Rapport Therapeutics beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to ImmunityBio?

Rapport Therapeutics (NASDAQ:RAPP) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Rapport Therapeutics presently has a consensus target price of $57.86, suggesting a potential upside of 39.79%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 108.36%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Rapport Therapeutics has higher earnings, but lower revenue than ImmunityBio. Rapport Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
ImmunityBio	$113.29M	63.00	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 8 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for ImmunityBio and 6 mentions for Rapport Therapeutics. ImmunityBio's average media sentiment score of 0.57 beat Rapport Therapeutics' score of 0.37 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
ImmunityBio	-606.15%	N/A	-59.53%

Summary

ImmunityBio beats Rapport Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Cogent Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Cogent Biosciences currently has a consensus price target of $45.90, indicating a potential upside of 7.83%. Rapport Therapeutics has a consensus price target of $57.86, indicating a potential upside of 39.79%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Rapport Therapeutics' return on equity of -24.78% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

In the previous week, Rapport Therapeutics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Rapport Therapeutics and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.52 beat Rapport Therapeutics' score of 0.37 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rapport Therapeutics beats Cogent Biosciences on 9 of the 12 factors compared between the two stocks.

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Rapport Therapeutics (NASDAQ:RAPP) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Mirum Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Mirum Pharmaceuticals	$521.31M	12.16	-$23.36M	-$13.61	N/A

Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Rapport Therapeutics currently has a consensus price target of $57.86, indicating a potential upside of 39.79%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 37.98%. Given Rapport Therapeutics' higher possible upside, research analysts clearly believe Rapport Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 6 mentions for Rapport Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Rapport Therapeutics' score of 0.37 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Rapport Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.98B	$11.48B	$6.80B	$12.89B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-15.92	791.51	279.90	25.40
Price / Sales	N/A	946.50	648.58	114.39
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	4.07	10.36	11.10	6.30
Net Income	-$111.48M	$2.80B	$3.48B	$347.60M
7 Day Performance	-1.36%	1.42%	1.93%	2.53%
1 Month Performance	6.21%	-3.36%	-3.29%	-2.57%
1 Year Performance	194.80%	154.79%	62.38%	20.26%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	2.8394 of 5 stars	$41.39 +1.5%	$57.86 +39.8%	+188.3%	$1.98B	N/A	N/A	N/A	Upcoming Earnings
PCVX Vaxcyte	2.7974 of 5 stars	$54.60 -1.6%	$86.00 +57.5%	+62.1%	$7.88B	N/A	N/A	160	Upcoming Earnings
RYTM Rhythm Pharmaceuticals	3.4138 of 5 stars	$108.04 +1.8%	$138.73 +28.4%	+16.4%	$7.40B	$189.76M	N/A	140	News Coverage Positive News Earnings Report Gap Up
IBRX ImmunityBio	2.4292 of 5 stars	$6.97 -0.3%	$14.20 +103.7%	+201.7%	$7.30B	$140.98M	N/A	590	Earnings Report Gap Down
COGT Cogent Biosciences	2.25 of 5 stars	$40.67 +0.6%	$45.90 +12.9%	+240.9%	$6.95B	N/A	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. PCVX, RYTM, IBRX, COGT, and MIRM

How does Rapport Therapeutics compare to Vaxcyte?

Summary

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Rapport Therapeutics compare to ImmunityBio?

Summary

How does Rapport Therapeutics compare to Cogent Biosciences?

Summary

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. PCVX, RYTM, IBRX, COGT, and MIRM

How does Rapport Therapeutics compare to Vaxcyte?

Do analysts recommend RAPP or PCVX?

Does the media favor RAPP or PCVX?

Is RAPP or PCVX more profitable?

Which has more volatility and risk, RAPP or PCVX?

Which has higher valuation and earnings, RAPP or PCVX?

Do institutionals & insiders have more ownership in RAPP or PCVX?

Summary

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Does the media prefer RAPP or RYTM?

Which has stronger earnings & valuation, RAPP or RYTM?

Do analysts prefer RAPP or RYTM?

Which has more volatility and risk, RAPP or RYTM?

Is RAPP or RYTM more profitable?

Summary

How does Rapport Therapeutics compare to ImmunityBio?

Do analysts rate RAPP or IBRX?

Which has better earnings & valuation, RAPP or IBRX?

Does the media refer more to RAPP or IBRX?

Do insiders and institutionals hold more shares of RAPP or IBRX?

Which has more risk & volatility, RAPP or IBRX?

Is RAPP or IBRX more profitable?

Summary

How does Rapport Therapeutics compare to Cogent Biosciences?

Which has more risk & volatility, COGT or RAPP?

Do analysts prefer COGT or RAPP?

Is COGT or RAPP more profitable?

Which has preferable valuation and earnings, COGT or RAPP?

Does the media favor COGT or RAPP?

Summary

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Which has better valuation and earnings, RAPP or MIRM?

Which has more volatility and risk, RAPP or MIRM?

Do analysts rate RAPP or MIRM?

Does the media prefer RAPP or MIRM?

Is RAPP or MIRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools